| Bid | 1.22 |
| Market Cap | 36.60M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.99 |
| PE Ratio (ttm) | -0.62 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.31 |
| Volume | 79,207 |
| Avg. Volume (20D) | 507,370 |
| Open | 1.27 |
| Previous Close | 1.26 |
| Day's Range | 1.22 - 1.28 |
| 52-Week Range | 0.87 - 21.55 |
| Beta | undefined |
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California....
Analyst Forecast
According to 5 analyst ratings, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 185.71% from the latest price.
2 months ago · businesswire.com
AN2 Therapeutics to Participate at Upcoming Investor ConferencesMENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c...
